{"filing":{"accession_number":"0001213900-26-077218","cik":"0001468492","ticker":"HSCSW","company_name":"HeartSciences Inc.","form":"8-K","filing_date":"2026-07-10","report_date":null,"primary_document":"ea0297481-8k_heartsci.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1468492/000121390026077218/ea0297481-8k_heartsci.htm"},"events":[{"id":17399,"run_id":15576,"accession_number":"0001213900-26-077218","anchor_item_number":"5.02","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.82,"summary":"HeartSciences amended the employment agreement of Danielle Watson (CFO) and granted her 25,000 RSUs in connection with a pending merger. The amendments modify severance provisions (six months base salary, COBRA, 100% acceleration of unvested equity), add discretionary performance bonus eligibility, and establish vesting conditions tied to the merger closing and continued employment.","company_name":"HeartSciences Inc.","ticker":"HSCSW","filing_date":"2026-07-10","form":"8-K","submitted_at":null,"items":[{"id":15850,"accession_number":"0001213900-26-077218","item_number":"3.02","item_title":"Unregistered Sales of Equity Securities","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"Item 3.02 discloses an unregistered issuance of equity securities (an \"Equity Award\"), but the disclosure explicitly cross-references Item 5.02 for substantive details. The reference to an \"Equity Award\" and the exemption analysis under Section 4(a)(2) and Regulation D indicate this is a compensatory equity grant to officers or directors rather than a capital-raising transaction. This is classified as exec_compensation because the core event is the grant of equity compensation, even though it appears under Item 3.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-11T00:13:48.695368+00:00","company_name":"","ticker":null,"filing_date":""},{"id":15851,"accession_number":"0001213900-26-077218","item_number":"5.02","item_title":"Departure of","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"The filing discloses amendments to Danielle Watson's (CFO) employment agreement and a new equity award in connection with a pending merger. The Watson EA Amendment modifies severance provisions (six months base salary, COBRA, 100% acceleration of unvested equity), adds discretionary performance bonus eligibility, and grants 25,000 RSUs with specific vesting conditions tied to the Closing and continued employment. While the section is titled Item 5.02 and mentions the merger context, the substantive disclosure centers on compensatory arrangements—severance modifications, bonus eligibility, and equity grants—rather than Watson's departure or appointment.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-11T00:13:48.695368+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":15850,"accession_number":"0001213900-26-077218","item_number":"3.02","item_title":"Unregistered Sales of Equity Securities","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"Item 3.02 discloses an unregistered issuance of equity securities (an \"Equity Award\"), but the disclosure explicitly cross-references Item 5.02 for substantive details. The reference to an \"Equity Award\" and the exemption analysis under Section 4(a)(2) and Regulation D indicate this is a compensatory equity grant to officers or directors rather than a capital-raising transaction. This is classified as exec_compensation because the core event is the grant of equity compensation, even though it appears under Item 3.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-11T00:13:48.695368+00:00","company_name":"HeartSciences Inc.","ticker":"HSCSW","filing_date":"2026-07-10"},{"id":15851,"accession_number":"0001213900-26-077218","item_number":"5.02","item_title":"Departure of","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.85,"reasoning":"The filing discloses amendments to Danielle Watson's (CFO) employment agreement and a new equity award in connection with a pending merger. The Watson EA Amendment modifies severance provisions (six months base salary, COBRA, 100% acceleration of unvested equity), adds discretionary performance bonus eligibility, and grants 25,000 RSUs with specific vesting conditions tied to the Closing and continued employment. While the section is titled Item 5.02 and mentions the merger context, the substantive disclosure centers on compensatory arrangements—severance modifications, bonus eligibility, and equity grants—rather than Watson's departure or appointment.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-11T00:13:48.695368+00:00","company_name":"HeartSciences Inc.","ticker":"HSCSW","filing_date":"2026-07-10"}]}